166 related articles for article (PubMed ID: 25692619)
21. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement.
Stahlschmidt J; Cullinane C; Roberts P; Picton SV
Med Pediatr Oncol; 1999 Dec; 33(6):551-7. PubMed ID: 10573578
[TBL] [Abstract][Full Text] [Related]
22. High frequency of loss of PTEN expression in human solid salivary adenoid cystic carcinoma and its implication for targeted therapy.
Liu H; Du L; Wang R; Wei C; Liu B; Zhu L; Liu P; Liu Q; Li J; Lu SL; Xiao J
Oncotarget; 2015 May; 6(13):11477-91. PubMed ID: 25909167
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Kim SJ; Shin DY; Kim JS; Yoon DH; Lee WS; Lee H; Do YR; Kang HJ; Eom HS; Ko YH; Lee SH; Yoo HY; Hong M; Suh C; Kim WS
Ann Oncol; 2016 Apr; 27(4):712-8. PubMed ID: 26861608
[TBL] [Abstract][Full Text] [Related]
24. A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Powles T; Wheater M; Din O; Geldart T; Boleti E; Stockdale A; Sundar S; Robinson A; Ahmed I; Wimalasingham A; Burke W; Sarker SJ; Hussain S; Ralph C
Eur Urol; 2016 Mar; 69(3):450-6. PubMed ID: 26364551
[TBL] [Abstract][Full Text] [Related]
25. Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors.
Lynch JT; Polanska UM; Hancox U; Delpuech O; Maynard J; Trigwell C; Eberlein C; Lenaghan C; Polanski R; Avivar-Valderas A; Cumberbatch M; Klinowska T; Critchlow SE; Cruzalegui F; Barry ST
Mol Cancer Ther; 2018 Nov; 17(11):2309-2319. PubMed ID: 30097489
[TBL] [Abstract][Full Text] [Related]
26. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
[TBL] [Abstract][Full Text] [Related]
27. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
Ito K; Mikami S; Tatsugami K; Masumori N; Shinohara N; Kondo T; Nakanishi S; Nagashima Y; Eto M; Kamba T; Kuroda N; Tomita Y; Matsuyama H; Onishi T; Tsushima T; Nakazawa H; Oya M; Ozono S; Naito S; Asano T
Clin Genitourin Cancer; 2018 Dec; 16(6):e1201-e1214. PubMed ID: 30224330
[TBL] [Abstract][Full Text] [Related]
28. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.
Goebell PJ; Doehn C; Grüllich C; Grünwald V; Steiner T; Ehneß R; Welslau M
Future Oncol; 2017 Jul; 13(17):1463-1471. PubMed ID: 28523933
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
30. PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer.
Milella M; Falcone I; Conciatori F; Matteoni S; Sacconi A; De Luca T; Bazzichetto C; Corbo V; Simbolo M; Sperduti I; Benfante A; Del Curatolo A; Cesta Incani U; Malusa F; Eramo A; Sette G; Scarpa A; Konopleva M; Andreeff M; McCubrey JA; Blandino G; Todaro M; Stassi G; De Maria R; Cognetti F; Del Bufalo D; Ciuffreda L
Sci Rep; 2017 Feb; 7():43013. PubMed ID: 28220839
[TBL] [Abstract][Full Text] [Related]
31. Renal Medullary Carcinoma: a Report of the Current Literature.
Blas L; Roberti J; Petroni J; Reniero L; Cicora F
Curr Urol Rep; 2019 Jan; 20(1):4. PubMed ID: 30656488
[TBL] [Abstract][Full Text] [Related]
32. SMARCB1/INI1 inactivation in renal medullary carcinoma.
Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
[TBL] [Abstract][Full Text] [Related]
33. Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
Park S; Shim JH; Lee B; Cho I; Park WY; Kim Y; Lee SH; Choi Y; Han J; Ahn JS; Ahn MJ; Park K; Sun JM
Lung Cancer; 2019 Aug; 134():7-15. PubMed ID: 31319998
[TBL] [Abstract][Full Text] [Related]
34. Clinical development of mTor inhibitors for renal cancer.
Ghidini M; Petrelli F; Ghidini A; Tomasello G; Hahne JC; Passalacqua R; Barni S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1229-1237. PubMed ID: 28952411
[TBL] [Abstract][Full Text] [Related]
35. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
Sodji Q; Klein K; Sravan K; Parikh J
J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
[TBL] [Abstract][Full Text] [Related]
36. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
37. Cystic presentation of a renal medullary carcinoma in a young woman.
Levi Sandri GB; Spoletini G; Lai Q; Mennini G; Rossi M
Urologia; 2015; 82(2):124-6. PubMed ID: 25451881
[TBL] [Abstract][Full Text] [Related]
38. Renal Medullary Carcinoma with an Aggressive Clinical Course: A Case Report and Review of the Literature.
Kalavar MR; Ali S; Safarpour D; Kunnakkat SD
Case Rep Oncol; 2017; 10(1):1-7. PubMed ID: 28203160
[TBL] [Abstract][Full Text] [Related]
39. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
40. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
